{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:22:16Z","timestamp":1775841736135,"version":"3.50.1"},"reference-count":20,"publisher":"Pharmaceutical Society of Japan","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2016]]},"DOI":"10.1248\/bpb.b16-00617","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T18:07:55Z","timestamp":1474049275000},"page":"2060-2065","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of the Safety Profiles of Pegylated Interferon \u03b1-2a and \u03b1-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study"],"prefix":"10.1248","volume":"39","author":[{"given":"Kazuki","family":"Ide","sequence":"first","affiliation":[{"name":"Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka"},{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University"},{"name":"Center for the Promotion of Interdisciplinary Education and Research, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University"},{"name":"Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Hawke","sequence":"additional","affiliation":[{"name":"Department of Scientific English, Graduate School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Drug Evaluation & Informatics, Graduate School of Pharmaceutical Sciences, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naohiko","family":"Masaki","sequence":"additional","affiliation":[{"name":"The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) World Health Organization. \u201cHepatitis C. Fact sheet No. 164.\u201d: \u2039http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/en\/\u3009, cited 28 July, 2016."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med.<\/i>, 368<\/b>, 34\u201344 (2013).","DOI":"10.1056\/NEJMoa1208953"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet<\/i>, 383<\/b>, 515\u2013523 (2014).","DOI":"10.1016\/S0140-6736(13)62121-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, Toyoda H, Genda T, Umemura T, Yatsuhashi H, Ide T, Toda N, Nirei K, Ueno Y, Nishigaki Y, Betular J, Gao B, Ishizaki A, Omote M, Mo HM, Garrison K, Pang PS, Knox SJ, Symonds WT, McHutchison JG, Izumi N, Omata M. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis.<\/i>, 15<\/b>, 645\u2013653 (2015).","DOI":"10.1016\/S1473-3099(15)70099-X"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology<\/i>, 146<\/b>, 1176\u20131192 (2014).","DOI":"10.1053\/j.gastro.2014.03.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med.<\/i>, 361<\/b>, 580\u2013593 (2009).","DOI":"10.1056\/NEJMoa0808010"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S. Randomized trial of peginterferon alpha-2a plus ribavirin versus<\/i> peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients. J. Gastroenterol.<\/i>, 47<\/b>, 1014\u20131021 (2012).","DOI":"10.1007\/s00535-012-0560-9"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Calvaruso V, Mazza M, Almasio PL. Pegylated-interferon-alpha(2a) in clinical practice: how to manage patients suffering from side effects. Expert Opin. Drug Saf.<\/i>, 10<\/b>, 429\u2013435 (2011).","DOI":"10.1517\/14740338.2011.559161"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M-H, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet<\/i>, 358<\/b>, 958\u2013965 (2001).","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J, International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon \u03b12b plus ribavirin for 48 weeks or for 24 weeks versus<\/i> interferon \u03b12b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet<\/i>, 352<\/b>, 1426\u20131432 (1998).","DOI":"10.1016\/S0140-6736(98)07124-4"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Minami T, Kishikawa T, Sato M, Tateishi R, Yoshida H, Koike K. Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. J. Gastroenterol.<\/i>, 48<\/b>, 254\u2013268 (2013).","DOI":"10.1007\/s00535-012-0631-y"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P. A comparison of peginterferon alpha-2a and alpha-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials. Clin. Ther.<\/i>, 32<\/b>, 1565\u20131577 (2010).","DOI":"10.1016\/j.clinthera.2010.08.009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig. Dis. Sci.<\/i>, 56<\/b>, 2221\u20132226 (2011).","DOI":"10.1007\/s10620-011-1765-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Masaki N, Yamagiwa Y, Shimbo T, Murata K, Korenaga M, Kanto T, Mizokami M, prefectural members contributing to the Japanese Interferon Database. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. BMC Public Health<\/i>, 15<\/b>, 566 (2015).","DOI":"10.1186\/s12889-015-1891-2"},{"key":"15","unstructured":"15) Ide K, Kawasaki Y, Yamada H, Masaki N. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study. Drug Des. Devel. Ther.<\/i>, 10<\/b>, 1217\u20131223 (2016)."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ide K, Kawasaki Y, Akutagawa M, Yamada H, Masaki N. Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan in both genotype 1 and genotype 2: A retrospective cohort study. Biol. Pharm. Bull.<\/i>, 39<\/b>, 1538\u20131543 (2016).","DOI":"10.1248\/bpb.b16-00408"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gonz\u00e1lez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M, International Pediatric Hepatitis C Therapy Group. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology<\/i>, 42<\/b>, 1010\u20131018 (2005).","DOI":"10.1002\/hep.20884"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika<\/i>, 81<\/b>, 515\u2013526 (1994).","DOI":"10.1093\/biomet\/81.3.515"},{"key":"19","unstructured":"19) Sato I, Shimbo T, Kawasaki Y, Masaki N. Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C: a retrospective study using the Japanese Interferon Database. Drug Des. Devel. Ther.<\/i>, 9<\/b>, 283\u2013290 (2014)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Wintrebert CMA, Putter H, Zwinderman AH, van Houwelingen JC. Centre-effect on survival after bone marrow transplantation: Application of time-dependent frailty models. Biom. J.<\/i>, 46<\/b>, 512\u2013525 (2004).","DOI":"10.1002\/bimj.200310051"}],"container-title":["Biological & Pharmaceutical Bulletin","Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/12\/39_b16-00617\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T19:01:22Z","timestamp":1498330882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/39\/12\/39_b16-00617\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b16-00617","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]}}}